These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 29027701)
21. Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Birner P; Toumangelova-Uzeir K; Natchev S; Guentchev M Folia Neuropathol; 2011; 49(2):88-93. PubMed ID: 21845536 [TBL] [Abstract][Full Text] [Related]
22. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345 [TBL] [Abstract][Full Text] [Related]
23. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Hayes J; Yu Y; Jalbert LE; Mazor T; Jones LE; Wood MD; Walsh KM; Bengtsson H; Hong C; Oberndorfer S; Roetzer T; Smirnov IV; Clarke JL; Aghi MK; Chang SM; Nelson SJ; Woehrer A; Phillips JJ; Solomon DA; Costello JF Neuro Oncol; 2018 Apr; 20(5):632-641. PubMed ID: 29077933 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923 [TBL] [Abstract][Full Text] [Related]
25. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199 [TBL] [Abstract][Full Text] [Related]
26. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Agnihotri S; Aldape KD; Zadeh G Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382 [TBL] [Abstract][Full Text] [Related]
27. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571 [TBL] [Abstract][Full Text] [Related]
28. Biomarker-driven diagnosis of diffuse gliomas. Appin CL; Brat DJ Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297 [TBL] [Abstract][Full Text] [Related]
29. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362 [TBL] [Abstract][Full Text] [Related]
30. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases. Jentoft M; Giannini C; Rossi S; Mota R; Jenkins RB; Rodriguez FJ Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114 [TBL] [Abstract][Full Text] [Related]
31. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Macaulay RJ Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765 [TBL] [Abstract][Full Text] [Related]
32. Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas. Gozé C; Mansour L; Rigau V; Duffau H J Neurosurg; 2013 Apr; 118(4):866-72. PubMed ID: 23330999 [TBL] [Abstract][Full Text] [Related]
33. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. Higgins RJ; Dickinson PJ; LeCouteur RA; Bollen AW; Wang H; Wang H; Corely LJ; Moore LM; Zang W; Fuller GN J Neurooncol; 2010 May; 98(1):49-55. PubMed ID: 19967449 [TBL] [Abstract][Full Text] [Related]
34. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128 [TBL] [Abstract][Full Text] [Related]
35. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917 [TBL] [Abstract][Full Text] [Related]
36. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. Chen R; Cohen AL; Colman H Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978 [TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072 [TBL] [Abstract][Full Text] [Related]
38. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors. Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217 [TBL] [Abstract][Full Text] [Related]
39. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis. Odia Y; Varma H; Tsankova NM Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263 [TBL] [Abstract][Full Text] [Related]
40. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]